Viral Genetics says VGV-1 effective in reducing viral load in some patients with AIDS

By Lisa Kerner

Charlotte, N.C., Aug. 11 - Viral Genetics, Inc. said results from its recent study of VGV-1 in AIDS indicate statistically significant reductions in the amount of HIV in the blood (viral load) in some patients, mild adverse events and a mechanism of action that may be markedly different than existing HIV therapies.

VGV-1, a suspension of thymus nuclear protein, also showed antiviral effects versus a placebo after 100 days of dosing in a recent 137-patient study. The immune-based therapy boosts the immune system, enabling the body to more efficiently fight HIV, according to a company news release.

The World Health Organization estimates approximately 40 million people are now living with HIV.

Viral Genetics is an Azusa, Calif.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.